While some companies were looking to profit from vaping off of a younger and vulnerable generation, Pneuma Respiratory was taking the necessary precautions to prevent a youth smoking epidemic. Pneuma Respiratory is a local to North Carolina’s Blue Ridge Mountains in Boone, NC, and since 2015 has been designing fully connected nanomist inhalers for smoking cessation and treating COPD and non-small cell lung cancer. 

With safety in mind, Pneuma designed their inhaler with integrated biometrics and an IoT platform to implement geo-fencing and prevent smoking in schools and public places where smoking is prohibited. Furthermore, the inhalers are equipped with sensors for monitoring certain health parameters and patient compliance during medical treatments. 

Pneuma’s inhaler can be used to safely deliver a plethora of drugs and pharmaceuticals such as nicotine, THC, CBD, ipratropium and albuterol. Delivering nicotine and cannabis products from an inhaler rather than a vape decreases the likelihood of creating toxic chemicals from heating the fluids, making it a safer alternative to combustion smoking and vaping.

Pneuma Respiratory is assigned to 4 US patents and 9 US patent applications as well as a family of PCTs, with their most recent patent, US Patent No. 10,525,220, granted January 7, 2020 for an inhaler device, which can be found in the Magic Number Cannabis sector tagged under Devices – Dosing Inhaler. Pneuma’s assets assisted them in raising nearly $5 million in April 2019.